1832 Asset Management L.P. Purchases 114,800 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

1832 Asset Management L.P. boosted its position in Axon Enterprise, Inc. (NASDAQ:AXON) by 44.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 375,700 shares of the biotechnology company’s stock after acquiring an additional 114,800 shares during the period. 1832 Asset Management L.P. owned 0.50% of Axon Enterprise worth $110,546,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Blue Trust Inc. lifted its holdings in Axon Enterprise by 987.5% during the second quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 79 shares during the period. ICA Group Wealth Management LLC bought a new stake in Axon Enterprise during the fourth quarter worth $26,000. Trivant Custom Portfolio Group LLC bought a new stake in Axon Enterprise during the first quarter worth $31,000. First PREMIER Bank bought a new stake in Axon Enterprise during the first quarter worth $33,000. Finally, Rise Advisors LLC lifted its holdings in Axon Enterprise by 49.0% during the first quarter. Rise Advisors LLC now owns 143 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 47 shares during the period. Institutional investors own 79.08% of the company’s stock.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, Director Matthew R. Mcbrady sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $364.66, for a total transaction of $729,320.00. Following the transaction, the director now owns 4,892 shares in the company, valued at approximately $1,783,916.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Michael Garnreiter sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $380.99, for a total value of $380,990.00. Following the transaction, the director now directly owns 27,259 shares of the company’s stock, valued at approximately $10,385,406.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Matthew R. Mcbrady sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $364.66, for a total value of $729,320.00. Following the completion of the transaction, the director now directly owns 4,892 shares in the company, valued at $1,783,916.72. The disclosure for this sale can be found here. Insiders have sold a total of 317,981 shares of company stock worth $115,662,734 in the last 90 days. Company insiders own 6.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Robert W. Baird raised their target price on Axon Enterprise from $360.00 to $400.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 10th. Barclays raised their target price on Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. JMP Securities lifted their price target on Axon Enterprise from $375.00 to $430.00 and gave the company an “outperform” rating in a research report on Thursday, September 12th. Bank of America started coverage on Axon Enterprise in a research report on Wednesday, July 17th. They issued a “buy” rating and a $380.00 price target for the company. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $400.00 price target on shares of Axon Enterprise in a research report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $365.38.

Axon Enterprise Trading Up 0.9 %

Shares of AXON stock opened at $393.29 on Friday. The company has a quick ratio of 2.52, a current ratio of 2.88 and a debt-to-equity ratio of 0.35. The business has a 50-day moving average price of $348.04 and a two-hundred day moving average price of $317.22. Axon Enterprise, Inc. has a 12-month low of $189.12 and a 12-month high of $393.58. The firm has a market cap of $29.68 billion, a P/E ratio of 115.00, a price-to-earnings-growth ratio of 10.34 and a beta of 0.94.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.18. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The company had revenue of $504.00 million during the quarter, compared to analyst estimates of $478.35 million. During the same quarter in the previous year, the company posted $0.80 EPS. Axon Enterprise’s revenue for the quarter was up 34.5% on a year-over-year basis. Equities analysts anticipate that Axon Enterprise, Inc. will post 1.79 EPS for the current fiscal year.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.